BAYW6228 COMPARED TO PLACEBO & LOVASTATIN IN PTS W/ PRIMARY HYPERCHOLESTEROLEMIA

BAYW6228 与安慰剂相比

• 批准号: 6116950
• 负责人: D ROGER ILLINGWORTH
• 金额: $ 3.13万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116950
• 关键词: antihypercholesterolemic agent; blood lipoprotein biosynthesis; clinical research; clinical trials; drug administration rate /duration; drug screening /evaluation; familial hyperlipoproteinemia type II; human subject; human therapy evaluation; hypercholesterolemia; inhibitor /antagonist; lovastatin; metabolism disorder chemotherapy; placebos

This study will evaluate the hypocholesterolemic effects and influence on cholesterol biosynthesis of the most potent inhibitor of cholesterol biosynthesis, BAYw6228, at doses of 50, 100, 200 and 300 ug/day in patients with primary hypercholesterolemia, As a control group, one oout of six patients will receive lovastatin (40 mg/day) and one out of six patients will receive placebo. Up to 30 patients will be involved in the study which will last for a total of 34 weeks.

本研究将评价降胆固醇的效果和对 胆固醇生物合成的最有效的抑制剂胆固醇 生物合成，BAYw 6228，在剂量为50，100，200和300微克/天， 原发性高胆固醇血症患者，作为对照组， 的6名患者将接受洛伐他汀（40 mg/天）， 患者将接受安慰剂。 多达30名患者将参与 这项研究将持续34周。